OLMA

#2511
Olema Pharmaceuticals, Inc. - Common Stock
10.2 7 USD
-0.05%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
10.27
10.27
Intervallo Annuale
7.76
36.26
Variazione giornaliera
-4.82%
Variazione Mensile
-10.15%
Variazione di 6 mesi
-56.34%
Variazione Annuale
+25.40%
Chiusura Precedente
10.7 9
Open
10.2 7
Minimo
10.2 7
Massimo
10.2 7
Volume
78
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Olema Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Olema Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Olema Pharmaceuticals, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Olema Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Olema Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Olema Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Olema Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Olema Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Olema Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Olema Pharmaceuticals, Inc. quarterly report, Q1 FY2026
10-Q

Olema Pharmaceuticals, Inc. current report, Q2 FY2025

Full document

Olema Pharmaceuticals, Inc. - 8-K Summary

Business Context and Reporting Period

This Form 8-K reports the results of the Annual Meeting of Stockholders held by Olema Pharmaceuticals, Inc. on June 10, 2025. The filing details the voting outcomes for director elections, executive compensation, and the ratification of the independent auditor.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.

Material Changes and Voting Results

The following matters were submitted to a vote of security holders:

  • Proposal 1: Election of Directors
    • Cynthia Butitta: 44,675,129 For; 11,733,848 Withheld.
    • Cyrus Harmon, Ph.D.: 43,838,514 For; 12,570,463 Withheld.
    • Graham Walmsley, M.D., Ph.D.: 44,120,432 For; 12,288,545 Withheld.
    • Outcome: All three nominees were elected as Class II directors until the 2028 annual meeting.
  • Proposal 2: Advisory Vote on Executive Compensation
    • Results: 54,057,177 For; 2,297,482 Against; 54,317 Abstain.
    • Outcome: Stockholders approved the compensation of named executive officers.
  • Proposal 3: Ratification of Independent Auditor
    • Results: 62,732,079 For; 24,064 Against; 14,528 Abstain.
    • Outcome: Stockholders ratified the selection of Ernst & Young LLP for the fiscal year ending December 31, 2025.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. For further details on executive compensation and director biographies, refer to the definitive proxy statement filed on April 28, 2025.

Investor Verification Checklist

  • Verify the total number of shares entitled to vote versus the number of votes cast to assess shareholder engagement levels.
  • Review the April 28, 2025 Proxy Statement for detailed executive compensation structures and director qualifications.
  • Confirm the tenure of the newly elected Class II directors (through 2028).
  • Note the significant number of broker non-votes (6,361,695) recorded for Proposals 1 and 2.

Notizie